logo
Products
Services
Resources
Selection Guides
About
XFD750 Anti-human CD38 Antibody
HI157
The HI157 monoclonal antibody binds to human CD38, a 45 kD transmembrane glycoprotein typically found on the surface of plasma cells, dendritic cells and myeloids. CD38 acts in important cellular pathways, in particular, the B cell receptor signaling pathway and apoptotic signaling pathway. Also, in many organisms, it acts to positively regulate vasoconstriction, acts to positively regulate cell growth and is a positive regulator of insulin secretion. From a research standpoint, it is of biological interest due to its association with essential macromolecules/ligands such as CD3/TcR complex, HLA Class II, Hyaluronic acid and CD31. CD38 is a fairly uncommon antibody target, with a little more than 10000 publications in the last decade. Even still, CD38 is often used in flow cytometry applications as a phenotypic marker for differentiation of cell types, specifically in the study of immunology. This antibody was purified through affinity chromatography and conjugated to XFD750 (ex/em = 752/776 nm). XFD750 is manufactured by AAT Bioquest, and it has a chemical structure similar to that of Alexa Fluor® 750 (Alexa Fluor® is the trademark of Thermo Fisher).
product image
CatalogSize
Price
Quantity
103811B0100 tests
Price
103811B1500 tests
Price
 
Antibody properties

Other namesADP-ribosyl cyclase, T10
CloneHI157
HostMouse
IsotypeIgG2a
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Correction factor (260 nm)0.00
Correction factor (280 nm)0.04
Extinction coefficient (cm -1 M -1)
240000
Excitation (nm)752
Emission (nm)776
Quantum yield
0.12
1
Usage and storage

Intended useResearch Use Only (RUO)
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on August 8, 2026